ORGCAR-19

N/A

Report date: 2025/01/07 15:46:20

Base Information

Drug NameORGCAR-19
Drug Alias NameORGCAR19ORGCAR-19CD19 CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLymphomaPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesKecellitics Biotech Company Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOrgenesis IncKecellitics Biotech Company Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphomaPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A